The Impact of Type 2 Diabetes on the Efficacy of ADP Receptor Blockers in Patients with Acute ST Elevation Myocardial Infarction: A Pilot Prospective Study

Table 3

Platelet aggregability and PRI of VASP-P in prasugrel- and clopidogrel-treated patients with acute STEMI (analysis of combined T2D and ND patients and analysis of T2D patients, marked as T2D patients).

LTA with ADP induction (%)	Prasugrel-treated patients	Clopidogrel-treated patients	Significance
Sample 1	45.9 ± 26.2%	59.2 ± 18.8%	< 0.05
Sample 2	24.9 ± 17.7%	51.7 ± 22.8%	< 0.001
LTA with ADP induction (%); T2D patients	Prasugrel-treated T2D patients	Clopidogrel-treated T2D patients	Significance
Sample 1	43.3 ± 20.6	63.5 ± 22.8	< 0.05
Sample 2	22.9 ± 16.9	60.3 ± 26.6	< 0.01
PRI of VASP-P analysis (%)	Prasugrel-treated patients	Clopidogrel-treated patients	Significance
Sample 1	52.7 ± 29.7%	68.9 ± 19.9	< 0.05
Sample 2	26.3 ± 24.3%	51.8 ± 22.8%	< 0.01
PRI of VASP-P analysis (%); T2D patients	Prasugrel-treated T2D patients	Clopidogrel-treated T2D patients	Significance
Sample 1	46.8 ± 33.5	78.3 ± 13.0	< 0.05
Sample 2	18.7 ± 15.7	56.8 ± 18.7	< 0.01